Description of Drug Utilization and Assessment of Impact of Saxagliptin on Health Status of Patients With Type 2 Diabetes in France (DIAPAZON)

AstraZeneca

Status: Completed

Conditions: Type 2 Diabetes Mellitus (T2D)

Treatments: Drug: Saxagliptin

Study type: Observational

Funder types: Industry

Identifiers

NCT01552005

CV181-148

Details and patient eligibility

About

The purpose of this study is to respond to The French Health Authority which has requested BMS France and Astra Zeneca (AZ) France to set-up a long-term cohort study in a representative sample of French Type 2 Diabetes mellitus (T2D) patients treated with Saxagliptin to generate real world data on drug utilization, joint population, non comparative effectiveness and safety

Full description

Time Perspective: Ambispective cohort follow by a 18 to 24 month follow up period, Retrospective follow by Prospective.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Registry

  • Patient ≥ 18 years old
  • Patient with T2D

• Ambispective Cohort

  • Patient ≥ 18 years old
  • Patient with T2D
  • Patient initiated with Saxagliptin in the last 6 months before the inclusion or day of inclusion visit (whatever his/her ongoing hypoglycaemic treatment)
  • Patient agreeing to participate, and not yet enrolled by another physician

Exclusion criteria

• Patient participating in a clinical trial

Trial design

1,000 participants in 1 patient group

Population of patients treated with Saxagliptin

Treatment:

Drug: Saxagliptin